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Introduction: Intensive monitoring (IM) is one of the methods of post-marketing active
surveillance based upon event monitoring, which has received interest in the current
medicines regulatory landscape. For a specific period of time, IM involves primary data
collection and is actively focused on gathering longitudinal information, mainly safety,
since the first day of drug use.
Objectives: To describe IM systems and studies’ data published over 11-years
period (2006–2016). Specifically, we reviewed study population/event surveillance,
methodological approaches, limitations, and its applications in the real-world evidence
generation data.
Methods: We completed a systematic search of MEDLINE and EMBASE to identify
studies published from 2006 to 2016, that used IM methodology. We extracted data
using a standardized form and results were analyzed descriptively. The methodological
quality of selected studies was assessed using the modified Downs and Black checklist.
Results: From 1,400 screened citations, we identified 86 papers, corresponding to
69 different studies. Seventy percent of reviewed studies corresponded to established
IM systems, of which, more than half were prescription event monitoring (PEM) and
modified-PEM. Among non-established IM systems, vaccines were the most common
studied drugs (n = 14). The median cohort size ranged from 488 (hospitals) to 10,479
(PEM) patients. Patients and caregivers were the event data source in 39.1% of studies.
The mean overall quality score was similar between established and non-established IM.
Conclusions: Over the study period, IM studies were implemented in 26 countries with
different maturity levels of post-marketing surveillance systems. We identified two major
limitations: only 20% of studies were conducted at hospital-level, which is a matter of
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concern, insofar as healthcare systems are facing a lack of access to new medicines at
ambulatory care level. Additionally, IM access to data of drug exposure cohorts, either
at identification or at follow-up stages, could somehow constitute a barrier, given the
complexity of managerial, linkable, and privacy data issues.
Keywords: adverse drug reaction reporting systems, clinical practice pattern, drug monitoring,
pharmacovigilance, systematic review
INTRODUCTION
Bridging the gap between information generated by randomized
clinical trials (RCT) and how to interpret different evidence
sources to better understand the real-world drug usage is of great
importance, since drugs often do not perform as well in RCT as
in routine clinical practice, the latter characterized by a variety
of sociocultural behaviors and clinical settings (1, 2). Overtime
this was clearly a lesson learned and nowadays society, including
payers, demands an integrated assessment of benefits and risks
under real life conditions as the next logical step after RCT (3, 4).
The adoption and use of real-world evidence (RWE), defined as
the clinical evidence regarding the usage and potential benefits
or risks of a medical product derived from analysis of routine
care data, is being increasingly important for regulatory decision-
making (5, 6). RWE can provide insights into key evidentiary
needs by regulators which include: (1) monitoring of medication
performance in routine care, including the effectiveness, safety
(e.g., labeling changes, withdrawals) and value; (2) identifying
new patient strata in which a drug may have added value or
unacceptable harms; and (3) monitoring targeted utilization (7).
In the last decades, a tale of withdrawals (8–10) has boosted
interest in pharmacovigilance and in response, regulators have
started to reform their systems, which have shifted from a largely
reactive response, that relied mainly on spontaneous reporting
(SR), to a more proactive approach to drug safety issues (11).
Specifically, in late 2005, the US Food and Drugs Administration
(FDA) and the European Medicines Agency (EMA) issued
guidance documents on therapeutic risk management planning
aimed at strengthening proactive postmarketing surveillance
(12). More recently, the European Union implemented new
pharmacovigilance legislation, where regulatory agencies have
now extended powers to demand for post-authorization efficacy
studies (PAES) in addition to post-authorization safety studies
(PASS) (13). Overall, it has been recognized that the knowledge
of drugs is no longer restricted to a binary decision at the time
of marketing authorization and the prevailing paradigm changed
from a risk centered approach to a benefit/risk assessment
throughout the medicine entire lifecycle (1, 14).
Framed onto the scope of all these regulatory changes,
intensive methods of post-marketing surveillance based on
drug event monitoring (15), known as intensive monitoring
(IM) methodology has been of interest (16–18). IM established
systems were launched in New Zealand [Intensive Medicines
Monitoring Program (IMMP)] (19) and in the UK [Prescription
Event Monitoring (PEM)] (20, 21), in the late 1970s and early
1980s, respectively. Since then, these systems and its background
methodology have evolved and been implemented in several
geographies worldwide, such as in the Netherlands [Lareb
Intensive Monitoring (LIM)] (11), Japan (22), or in some African
countries (23).
As compared to SR system that passively monitors all drugs
during their whole life cycle and cover all population (24, 25).
IM combines the strengths of pharmacoepidemiological and
clinical pharmacovigilance approaches and focuses on specific
drugs. For a specific period of time, IM involves primary data
collection and is defined as an observational inception cohort
of subjects exposed to the drug(s) of interest (26). IM cohorts
of drug exposures are identified either through prescribers (e.g.,
PEM), pharmacies (e.g., IMMP), and national pharmacovigilance
systems (e.g., LIM) and followed in a systematic and prospective
fashion through a large variety of sources (e.g., patients,
prescribers, and hospitals).
Although IM systems were developed more than 30 years ago,
there has not been a global comprehensive synthesis of event
drug monitoring research studies to date. The purpose of this
systematic review is to describe IM systems and studies’ data
published in the decade following the paradigm shift inmedicines
regulatory assessment, which was largely characterized by a more
proactive approach to drug safety issues. From 2006 to 2016, we
reviewed study population/event surveillance, methodological
approaches (including data collection sources and analysis),
limitations, main outcomes of interest, and IM applications in the
real-world evidence generation data.
MATERIALS AND METHODS
This study followed current guidance of conducting and
reporting systematic reviews, including guidance for undertaking
reviews in health care on public health intervention reviews by
the Center for Reviews and Dissemination of the University of
York (27) and recommendations from the PRISMA-P statement
regarding reporting items (28). The protocol for this review
was registered at PROSPERO (CRD42017069309) available
at https://www.crd.york.ac.uk/PROSPERO/display_record.asp?
ID=CRD42017069309.
For inclusion in the review, papers had to report data on an IM
study/system as defined above. RCT, studies conducted through
automated databases (e.g., claims or electronic health/medical
records), registries, SR schemes and case-reports/series were
excluded. No restriction on study population, intervention,
outcomes and comparator was imposed for study selection,
although we only included studies published in English,
Portuguese, Spanish, Italian, or French. Letters to editor and
conference proceedings were also excluded, as these materials
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often reflect preliminary analysis and it is less likely that methods
and results are described with the necessary details.
Electronic database identification of reports was undertaken
on MEDLINE and EMBASE via OVID SP interface from
inception to the 20th of April 2017, to include studies published
on the time-frame of interest: January 2006 to December
2016. Complementary searches were made to identify potential
additional articles: reference checking and hand-searching. The
search strategy was developed after several iterations and it is
presented in Additional File 1.
References located and potentially eligible for inclusion were
exported to an Excel R© file where authors recorded eligibility
criteria of selected abstracts and full paper references. The
abstracts were independently checked against the inclusion
criteria by CT, MC, and PB and classified as include, unclear or
exclude. The full reports for all articles that classified as include or
unclear were retrieved, and two authors (CT, MC) independently
evaluated its eligibility criteria for inclusion. All disagreements
were resolved by discussion or, if necessary, by arbitration by
a third review author (AM). The main reasons for exclusion,
either at the title/abstract or at the full text screening phases
were recorded.
Data from included papers were extracted by three authors
(MC, CT, PB) and validated by a fourth author (FB), using
a standardized data extraction form designed and pre-piloted
for this review. This form was designed to systematically
retrieve information from each included study on the following
items: (1) general characteristics: title, first author, citation,
year of publication and country, (2) type of IM system: (2.1)
established systems: Cohort event monitoring (CEM), IMMP,
LIM, PEM, or Modified-PEM (M-PEM) or (2.2) non-established
systems/single IM studies, (3) background & rationale, (4)
research question, (5) setting, (6) study design, (7) population
eligibility criteria, (8) drugs studied [classified according to the
Anatomical Therapeutic Chemical classification (ATC) from
World Health Organization (WHO)] (29), (9) methods and
data collection (variables), (10) drug domains studied, (11)
data sources of events reporting [patients/caregivers (PCG),
healthcare professionals (HCP)], (11) data analysis, (12) duration
of follow-up and study time frame, (13) number of patients
included, (14) limitations pointed by the authors, (15) authors’
conclusions, (16) applications, and (17) sources of funding.
One review author (FB) assessed the risk of bias of the
included studies using the modified Downs and Black assessment
checklist (30), for the risk of bias and the quality of both
randomized and non-randomized studies. Data was validated
by another reviewer (CT) and the rationale behind assessments
was documented. The Downs and Black assessment checklist was
selected for the following reasons: (1) in an evaluation by Deeks
et al. (31), it was one of the six instruments considered most
suitable for use in systematic reviews of non-randomized studies,
out of 182 tools identified; (2) it was recommended as one of the
most useful tools for assessing risk of bias in non-randomized
studies both by Cochrane Collaboration and the Agency for
Healthcare Research and Quality (32). As some items of the
Downs and Black checklist are only applicable to randomized
studies and since the majority of published IM studies are a
single-arm design, the Downs and Black checklist was adapted
for the purpose of this review as provided in Additional File 2.
Our modified checklist included a total of 13 topics out of the 27
of the original version. Consequently, the overall quality score of
each study ranged between 0 and 13.
The data synthesis was descriptive as the main aim of this
systematic review was to identify methods, not quantify any
effect. Data from the included studies were described and
presented in text, tables and figures. When multiple papers
were retrieved from the same IM study (e.g., results at different
follow-up periods or reporting at different outcomes/drug study
domains) they were treated as a single study.
RESULTS
Literature Search
The search and screening process is summarized in Figure 1. A
total of 1,430 references were identified through the electronic
searches of the databases. Ten additional records were identified
through hand searches. After 40 duplicates were removed, we
obtained 1,400 citations, which were screened by title and
abstract. We excluded 1,293 citations as they did not meet
the inclusion criteria, and the remaining 107 were screened
full text. Twenty-one citations were further excluded (33–52)
and 86 papers were included, corresponding to 69 different
studies (53–138).
Overview of Studies
The included studies were conducted in 26 countries. Overall,
70% of studies corresponded to established IM systems: PEM
(n = 18), M-PEM (n = 8), CEM (n = 12), LIM (n = 6), and
IMMP (n = 4). The remaining (n = 21) were single studies
conducted within the IM methodology framework but were not
part of any established IM. These studies were grouped in three
categories: Vaccines (n= 14), Hospital setting based (n= 5), and
Others (n = 2). Tables 1, 2 summarize the main characteristics
(drugs monitored ATC, drug domains studied, event data source,
methods of data collection and countries where the studies were
conducted) of established and non-established IM systems. Data
extracted from all included studies are presented in Table 3.
Established IM Systems
PEM and M-PEM represented the majority of the studies
included (n = 26). Concerning PEM studies, the median study
duration was 35.5 months (range: 8–55) and the duration of
patient follow-up varied between 2 and 12 months (median:
6.0). Similar results were found for M-PEM studies. The median
number of patients per study was 10479.5 (range: 1,728–
28,357) and 7419.5 (range: 551–26,877), for PEM and M-PEM
studies, respectively. For both schemes, it was stated that all
studies were conducted with unconditional funding from the
pharmaceutical industry. The common limitations pointed out
by the authors was the non-return by general practitioner (GP)
of questionnaires (which might result in non-response bias if
the characteristics of patients at responding GP practices differ
from those at non-responding GP practices), under-reporting
and the restriction to primary care setting. Furthermore, the
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Records identified 
through database 
searching, n=1430
Records identified 
through other sources, 
n=10
Duplicates removed, 
n=40
Records screened by 
title and abstract, 
n=1400
Records excluded n=1293
-Conference, n=521
- Language, n=13
-Study design (or were not an IM/based 
upon event monitoring), n=759 
Full text screening, 
n=107
Records excluded n=21
- Study design (or were not an IM/based 
upon event monitoring), n=20
- Language, n=1
Number of papers included, n=86*
*That corresponds to 69 studies
FIGURE 1 | Flow chart of literature search.
lack of a concurrent control (single-group cohort design) was
also addressed as a limitation, leading to a knowledge gap on
the true background incidence for events. Unlike PEM, the M-
PEM methodology offered a greater scope to collect information
on confounding variables, since a more detailed study-specific
questionnaire was used.
Considering CEM studies, the median study and patient
follow-up duration, was 10.0 (range: 0.5–109) and 0.7 months
(range: 0.2–12), respectively. The median cohort size was 4,789
(range: 228–23,988) patients. Five out of 12 studies were
conducted with no sources of funding, 6 studies were financially
supported by either governmental institutions (n = 3), non-
governmental institutions (n = 2) or both (n = 1) and one
study was financed by the pharmaceutical industry. Lack of
generalizability (selection bias concerning patients’ enrolment
and high cohort drop-out rates), baseline events reported as
“true” adverse drug events (ADE) (e.g., antimalarials studies
with no event collection before vs. after treatment), costly and
resource labor intensive for data collection and management
were described as limitations of concern.
LIM studies reported the lowest cohort size among the
established IM systems. Overall, a median number of 1462.5
(range: 398–3,569) patients were enrolled. The median study
duration for the 5 out of 6 studies where this information was
available, was 24 months (range: 7–63) and patients’ follow-up
duration varied between 1 and 12 months (median: 5.0). The
majority of the LIM studies (n = 3) did not report the source
of funding, 2 studies were conducted with financial support from
governmental institutions and one was implemented without any
source of funding. Limitations raised were in line with other
established IM systems. LIM studies reported event rates rather
than true incident rates and no information was provided about
the patients that did not accept to participate (e.g., older people
might be underrepresented since they do not have access/are not
familiar with internet). Furthermore, since the patients were the
source of event information, those who experienced an adverse
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TABLE 1 | Established intensive monitoring systems overall main characteristics.
CEM (n = 12) IMMP (n = 4) LIM (n = 6) PEM (n = 18)/M-PEM (n = 8)
Countries BF, BY, GH, LK, MD, MZ, NG,
SN, TZ
NZ NL UK
Methods of data
collection
CEM was established by
WHO. Cohort is enrolled by
HCP instead of relying on
prescription data supplied by
pharmacies. Eligible patients
are interviewed or given a
questionnaire after enrolment.
Patients are followed-up after a
defined interval to record any
new events after starting
treatment with the monitored
medicine. Event data is
collected in medical or nursing
appointments, by phone or
during home visits.
IMMP operates within the NZPhvC.
Patients cohorts are established
from prescriptions data received
from pharmacies nationwide.
Questionnaires requesting
information on all new events are
sent to prescribing physicians
(usually GP). Additional information
is obtained from record linkage to
other databases (e.g., deaths,
hospital admissions) and SRS
(reports sent by HCP, HCG and
pharma companies).
LIM was developed by the national
Dutch pharmacovigilance center
Lareb. First time users are identified
in community pharmacies (but other
inclusion points are possible: e.g.,
GP). Baseline (registration) and event
data are collected using web-based
questionnaires which are sent to
patients at specific time follow-up
points. Data obtained reflect
information from patients’
perspective
PEM/M-PEM are implemented by
DSRU. Patients are identified from
NHS first dispensed prescriptions.
Questionnaires are sent to GP to
collect patient characteristics, drug
exposure and event data. M-PEM
differs from PEM in that a more
detailed study-specific
questionnaire is used (e.g., capture
specific events, drug exposure,
relevant disease risk factors at
treatment start)
Studied domains Safety, drug utilization patterns
and effectiveness
Safety, drug utilization patterns and
effectiveness
Safety and drug utilization patterns Safety and drug utilization patterns
Setting| Event data
source
AMB, HOSP| HCP, PCG AMB| HCP AMB| PCG AMB| HCP
ATC Antiinfectives for systemic use
(J) and antiparasitic products,
insecticides and repellents (P)
Alimentary tract and metabolism (A)
and nervous system (N)
Alimentary tract and metabolism (A),
antiinfectives for systemic use (J),
and nervous system (N)
Alimentary tract and metabolism
(A), cardiovascular system (C),
genito urinary system and sex
hormones (G), musculo-skeletal
system (M), nervous system (N),
and respiratory system (R)
AMB, Ambulatory care level; BF, Burkina Faso; BY, Republic of Belarus; CEM, Cohort Event Monitoring; DSRU, Drug Safety Research Unit; GH, Ghana; GP, General practitioner; HOSP,
Hospital care level; HCP, Healthcare Professionals; IMMP, Intensive Medicines Monitoring Programme; LIM, Lareb Intensive Monitoring; LK, Sri Lanka; MD, Madagascar; M-PEM,
Modified-Prescription Event Monitoring; MZ, Mozambique; NG, Nigeria; NHS, National Health Service; NL, The Netherlands; NZ, New Zealand; NZPhvC, New Zealand Pharmacovigilance
Center; PCG, Patient/Care Giver; PEM, Prescription-Event Monitoring; SN, Senegal; TZ, Tanzania; UK, United Kingdom; WHO, World Health Organization.
TABLE 2 | Non-established intensive monitoring (IM) systems: studies characteristics.
Vaccines (n = 14) Hospital based (n = 5) Others (n = 2)
Countries AU, BR, CN, FR, GT, NL, SA, TN, USA, UK AE, GR, IT, MX, TW FR, JP
Domains studied Safety and effectiveness Safety, drug utilization patterns and effectiveness Safety and effectiveness
Setting|Event data source AMB| HCP, PCG HOSP| HCP, PCG AMB| HCP
ATC Antiinfectives for systemic use (J) Blood and blood forming organs (B), antiinfectives for
systemic use (J), antineoplastic and immunomodulating
agents (L), and various (V)
Cardiovascular system (C)
AMB, Ambulatory care level; AE, United Arab Emirates; AU, Austria; BR, Brazil; CN, China; FR, France; GR, Greece; GT, Guatemala; HOSP, Hospital care level; HCP, Healthcare
Professionals; IT, Italy; JP, Japan; MX, Mexico; NL, The Netherlands; PCG, Patient/Care Giver; SA, Saudi Arabia; TN, Tunisia; TW, Taiwan; UK, United Kingdom; USA, United States of
America; VAC, Vaccines.
drug reaction (ADR) might be more motivated to fill in a
questionnaire than those who did not experience it (reporting
bias). It was also stated as a limitation the difficulty in obtaining
information about serious and fatal outcomes.
The median number of patients from IMMP studies was 6,891
(range: 420–17,298). The median study duration was similar to
PEM studies, however a higher duration of follow-up time period
(median: 15 months; range: 2–20) was observed. All studies
received funding from governmental institutions and 2 studies
were unconditionally co-funded by pharmaceutical industry. Not
all IMMP studies reported limitations. From those studies where
this information was available, an absence of a comparator
group, underestimation of ADE rates and limited clinical detailed
information were issues pointed out. Further, in the study of
varenicline (92), the “effectiveness assessment” was performed
based on information provided by the reporting doctor and for
many patients, it was unknown whether varenicline was effective.
Non-established IM Systems
Two-thirds of non-established IM studies reported the IM of
vaccines, half of those were related to the influenza H1N1
2009 pandemic vaccine. Almost all vaccines’ studies (13 out
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TABLE 3 | Detailed results regarding included publications.
IM Studies ATC Aim Size (n);
SD; DFU
Applications Conclusions QS
Established intensive monitoring systems
CEM
(66)
Artemether and lumefantrine
(P01BF01) and artesunate and
amodiaquine (P01BF03)
Determining the safety profile of
artemisinin-based combination
therapies
10,259;
5; 0.2
Complement limited information from RCT.
Importance of an active surveillance method
in countries with low pharmacovigilance
activities
Artemisinin-based combination therapies
are generally safe, effective and remarkably
well-tolerated among Nigerian populations
9
CEM (112) Artemether and lumefantrine
(P01BF01)
Establish the safety of artemether
and lumefantrine in public health
facilities in Tanzania
8,040;
34; 0.2
Complement the SRS for monitoring the
safety of medicines of public health interest.
CEM is a reliable pharmacovigilance tool in
Tanzania
The safety profile of these drugs is
favorable for the treatment of
uncomplicated malaria. No major safety
concerns were observed. Most of the
observed AEs were already documented
9
CEM
(125)
Encephalitis, Japanese, live
attenuated (J07BA03)
Describe the safety profile of
Japanese encephalitis vaccine in
the immunization programme of
Sri Lanka
3,041;
26; 1.5
Potential to identify unrecognized and
unsuspected AEFI. Evidence generated
strengthened the existing knowledge
obtained via other studies
Life attenuated Japanese encephalitis
vaccine administered at the age of 9
months is relatively safe. The AEFI were
mostly non-serious
6
CEM
(64)
Fixed-dose combination of
dihydroartemisinin and
piperaquine phosphate
(P01BF05)
Assess the clinical safety of
dihydroartemisinic/piperaquine in
four African countries
11,028;
11; 0.9
Phase IV assessment as part of the RMP.
Feasible to conduct safety monitoring of
more than 10,000 patients, including
electrocardiography monitoring
The treatment was well-tolerated. QT
interval prolongation may occur in children
10
CEM
(126)
Zidovudine (J05AF01), lamivudine
(J05AF05), tenofovir (J05AF07),
nevirapine (J05AG01) and
efavirenz (J05AG03)
Evaluate the safety profile of the
highly active antiretroviral
treatment
518;
24; 12
Gather data on ADRs in resource limited
settings with different populations compared
with RCT (e.g., North America, Europe).
Contribution patient care/therapy
optimization
Achievement of a favorable benefit-risk
ratio for highly active antiretroviral therapy
could require more vigilant consideration
and careful assessment before therapy
commencement and further regular
monitoring of key laboratory parameters
7
CEM
(130)
Zidovudine (J05AF01), lamivudine
(J05AF05) and lopinavir-ritonavir
(J05AR10)
Assess the IR of AEs and
adherence in
occupationally-exposed
healthcare workers and
healthcare students
228;
78; 6
Effectively conduct an active safety
monitoring of ARVs in resource limited
settings where the SPRS and healthcare
systems yield very little data
AE are very common and could be
severe/serious in some cases. Intolerance
to AE was cited as the sole reason for
truncating treatment, indicating the need
for effective counseling, active follow-up
and AE management
9
CEM
(76)
Encephalitis, Japanese,
inactivated, whole virus
(J07BA02)
Describe the IR and profile of
overall AEs
9,798;
2; 0.5
Evidence generation on AEFI before
strategizing to boost the confidence of
general public on vaccination in endemic
districts
IR of AEFI was several-fold higher than
that reported through the national
surveillance system.IR of seizures was low
and vaccine related other neurological
manifestations were absent
9
CEM
(53, 80)
Quinine (P01BC01),
pyrimethamine, combinations
(P01BD51), artemisinin
(P01BE01), artemether
(P01BE02), artesunate
(P01BE03), artemisinin and
derivatives, combinations
(P01BF), artemether and
lumefantrine (P01BF01),
artesunate and amodiaquine
Gather drug utilization and AE
data for patients prescribed
antimalarial medicines in an
outpatient setting
2,831;
9; 0.9
Knowledge of drug utilization patterns is key
in understanding patient management and
consequent drug safety issues. One third of
patients received an artemisinin
monotherapy (not recommended by WHO
due to the potential for drug resistance),
highlighting the urgent need to educate
health care workers for guidelines adoption.
Also, improving malaria diagnostic test
availability should be a priority
The first-line therapy was adhered to in
<50% of cases. Captured events reflected
the types of events expected and nearly all
events reported are listed in the SPC of
monitored medicines. Concerning drug
utilization patterns, this study suggests an
important role for confirmatory diagnostics
in rational prescribing
11
(Continued)
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TABLE 3 | Continued
IM Studies ATC Aim Size (n);
SD; DFU
Applications Conclusions QS
(P01BF03), artesunate,
sulphamethopyrazine and
pyrimethamine (P01BF04) and
quinine and derivatives (M09AA)
CEM
(56)
Influenza, inactivated, split virus or
surface antigen (J07BB02)
Determine the distribution and
types of AEs reported following
immunization
5,870;
0.5; 0.2
Detection of serious event and signal
generation (some reported AEs not yet
included in the SPC: tachycardia, tinnitus,
and decreased appetite)
The most prominent AEs reported were
headaches, dizziness, muscle and joint
aches, weakness, fever and injection-site
pain. The types of AEFI reported were
similar to other studies but the frequency
of occurrence did not follow the same
pattern
9
CEM
(65)
Artemether and lumefantrine
(P01BF01) and fixed-dose
combination: artesunate and
amodiaquine (P01BF03)
Determine the AEs profile of
artemisinin-based combination
therapies in real-life settings
3,010;
4; 0.2
Complement limited information from RCT.
Importance of an active surveillance method
in countries with low pharmacovigilance
activities
AEs among the Nigerians were similar to
those reported in the literature, including
general body weaknesses, dizziness,
vomiting, loss of appetite, and abdominal
pain. The monitored drugs are
well-tolerated among Nigerians
10
CEM
(68)
Fixed-dose combination of
artesunate and amodiaquine
(P01BF03)
Testing CEM performance and
feasibility in routine practice in
malaria-endemic country
3,708;
109; 0.9
Complement limited information from RCT.
Quantifying and characterizing known ADR;
generating information on safety, tolerability
and practical aspects
CEM-based system is feasible, but more
research is needed to assess sustainability
and conditions to make it cost-effective,
including the amount and quality of data
generated
10
CEM (78) Sulfadoxine-pyrimethamine
(P01BD51)
Evaluate the safety profile and
identify potential new AEs
23,988;
8; 0.3
Simultaneous administration of
sulfadoxine-pyrimethamin and routine
immunizations is a safe strategy (low risk of
serious AEs to infants)
Sulfadoxine-pyrimethamine is an efficient
malaria control intervention with an
acceptable safety profile
10
IMMP
(90–92,
107)
Varenicline (N07BA03) Describe the drug utilization of
varenicline and identify ADRs
(specifically psychiatry and
cardiovascular events). To
determine the extent of exposure
during pregnancy (identify the
relevant maternal and fetal
outcomes)
13,176;
48; 15
Identification of a significant number of
women exposed to varenicline during
pregnancy. Cardiovascular events were
identified (including in patients with no
known history of cardiovascular disease)
Dispensing data showed that the majority
of patients did not receive 12 continuous
weeks of varenicline treatment as
recommended. Psychiatric and
cardiovascular adverse events were
commonly reported in patients taking
varenicline. Approximately 1% of women
of reproductive age prescribed varenicline
may be exposed to this medicine during
pregnancy
10
IMMP
(89)
Clozapine (N05AH02), olanzapine
(N05AH03), quetiapine
(N05AH04) and risperidone
(N05AX08)
Compare nocturnal enuresis in
patients taking clozapine with that
in patients taking risperidone,
olanzapine or quetiapine
606;
15; 15
Accurately reflect the occurrence of
nocturnal enuresis in ‘real-life’ use.
Increased awareness of bed-wetting should
lead to improved patients’ care
This study showed that bed-wetting is
relatively common, with about 21% of
patients on clozapine (and around 10% of
patients on other atypical antipsychotic
medicines) likely to suffer this unpleasant
and embarrassing AE
11
(Continued)
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TABLE 3 | Continued
IM Studies ATC Aim Size (n);
SD; DFU
Applications Conclusions QS
IMMP
(88, 95)
Sibutramine (A08AA10) Describe the patterns of
sibutramine usage and to quantify
the risk of fatal and non-fatal
cardiovascular events
17,298;
50; 12
Complete picture of usage (monitoring of
populations outside SPC: <18 years and
≥65 years)—IMMP population was younger;
higher proportion of females; quantification
of cardiovascular risks in general population
Extensive use of sibutramine. Some
factors may have contributed to the
predominantly short-term use, including
costs, weight loss not meeting
expectations and AEs. The risk of death
from a cardiovascular event in the general
population was lower than has been
reported in other overweight/obese
populations
10
IMMP
(87)
Clozapine (N05AH02), olanzapine
(N05AH03), quetiapine
(N05AH04) and risperidone
(N05AX08)
Investigate safety and usage of
typical antipsychotic medicines in
a nationwide pediatric population
420;
20; 20
Real-life picture of safety and usage of
atypical antipsychotics in children.
Identification of depression as a new signal
for risperidone in children
Most prescriptions were for risperidone
(common diagnosis: disruptive disorders).
Unexpected use for sleep disorders’
treatment. Depression was identified as a
potential new signal for risperidone
8
LIM
(77)
Metformin (A10BA02) Gather information about
frequency, latency time, outcome
and management of ADRs in daily
practice
2,490;
63; 12
Investigate detailed information about time
course, outcome and management of ADRs
to help clinicians and patients in adequate
predicting and handling of drug related
ADRs (improve adherence & avoid early
discontinuation)
The median latency time of the most
frequently reported. ADRs is <7 days. In
the majority of cases, no action was taken
according to metformin after the
occurrence of ADRs. The findings are in
line with SPC; the safety profile in daily
practice is relatively safe
9
LIM
(134)
Influenza, inactivated, split virus or
surface antigen (J07BB02)
Evaluate the feasibility of the LIM
system during the annual
influenza vaccination
1,507; NM; 1 Insight into the pattern, time course,
outcome, severity and possible risk factors
of AEFIs compared to SRS
Intensive monitoring of AEFI is a feasible
method based on willingness and
possibility of participants to complete the
questionnaires. The pattern of AEFI was
comparable with the reported AEFI in
spontaneous reports
9
LIM
(115)
Varenicline (N07BA03) Gain insight in the safety and use
of varenicline in daily practice
1,418;
44; 4
Provide insight into the occurrence, latency
time of ADRs and action taken with
varenicline when ADRs occur. This
information can be used for patients’ advice
(e.g., patients who start this drug)
The median reported latency times of
ADRs were mostly 3–7 days, and they
were mentioned with the same overall
frequency as in SPC of varenicline. After
experiencing nausea, abdominal pain or
abnormal dreaming as possible ADRs,
patients usually did not stop using
varenicline
9
LIM
(86)
Duloxetine (N06AX21) Describe the user and safety
profile of duloxetine in daily
practice
398;
24; 6
Identification of new signals of possible new
ADRs (amenorrhoea, shock-like
paraesthesia, and urinary disorders)
The ADR profile of duloxetine as reported
by patients is overall similar to the profile
described in the SPC, but 3 new signals
were identified and need further
evaluation. Four patients experienced
SADR (one was fatal)
9
(Continued)
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TABLE 3 | Continued
IM Studies ATC Aim Size (n);
SD; DFU
Applications Conclusions QS
LIM
(85)
Influenza, inactivated, split virus or
surface antigen (J07BB02)
Identify and quantify the AEFIs
associated with the pandemic
vaccine
3,569;
7; 3.2
Possibility to follow the time course of the
AEFIs and to collect information about
latency, recovery and duration
AEFIs due to pandemic vaccination
occurred in 1/3 of participants and did not
raise any concerns about the safety of
vaccine. AEFIs reported were expected
and non-serious
11
LIM
(83, 84)
Pregabalin (N03AX16) Gain insight into the user profile
and longitudinal safety of
pregabalin in daily practice
1,373;
24; 6
Contribute to improve knowledge about
ADRs characteristics (IR, time course).
Identification of new signals (abdominal pain,
suicidal ideation and possible interaction
with oral antidiabetics)
Pregabalin is a relatively safe drug in daily
practice. <1.0% out of the total population
experienced a serious ADR. The most
frequently reported ADRs correspond to
those that were most frequently reported
during RCT
9
M-PEM
(106)
Vildagliptin (A10BH02) Investigate the pattern of onset
and effect of vildagliptin
combination therapy on
peripheral oedema risk
4,828;
40; 6
Assess the occurrence of a specific AE
identified within the RMP and predictors of
risk
Peripheral oedema occurred most
frequently within 1 month after starting
treatment, and previous peripheral
oedema history and male sex in elderly
patients were important predictors of this
risk. Concomitant use of a sulfonylurea
may also increase the risk of this event
11
M-PEM
(119)
Quetiapine (N05AH04) Present a description of drug
utilization characteristics
13,276;
66; 12
PASS as part of the RMP requirements:
assess the long-term use (drug utilization
data—determinants of prescribing and
cohort characteristics) of quetiapine
The prevalence of off-label prescribing
(indication and high doses) was common,
as was used in special populations (e.g.,
very elderly). Whilst off-label use may be
unavoidable in certain situations, GPs may
need to re-evaluate prescribing where
there may be safety concerns
10
M-PEM
(105)
Fentanyl (N02AB03) Examine the use (identify potential
misuse or inappropriate/off label
use) of fentanyl as prescribed in
primary care
551;
32; 6
PASS as part of the RMP requirements.
Feasibility of the systematic collection of
physician reports of risk factors for
dependence, misuse and aberrant behaviors
The prevalence of at least one pre-existing
risk factor for dependence was 26%,
whilst the frequency of aberrant behaviors
observed during treatment was 8%.
Patients with aberrant behaviors had
several different characteristics to patients
without
10
M-PEM
(71, 100)
Varenicline (N07BA03) Estimate the IR and the pattern of
AE reported
12,159;
7; 3
Characterization of real life drug use;
hypothesis testing on pre-specified events
based on regulatory warnings (e.g.,
psychiatric and cardiovascular)
No signal was raised using the IR
differences approach, and only anxiety
was flagged as a potential signal. Further
evaluation is needed to determine if
anxiety is drug related or withdrawal
symptom cause by smoking cessation
11
M-PEM
(70, 138)
Rimonabant (A08AX01) Explore possible relationships
between patient characteristics
and reasons for discontinuation;
compare the risk of depressive
episodes prior and after treatment
10,011;
24; 6
Collection of detailed information on safety
issues in daily clinical practice. Assessment
of risk of specific psychiatric/nervous system
events of regulatory concern
Reasons for and time to discontinuation
were associated with patient
characteristics (e.g., medical history).
Patients discontinued treatment because
of psychiatric events early after starting.
Regarding depressive episodes, there was
no increased risk whilst taking rimonabant
11
(Continued)
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Applications Conclusions QS
M-PEM
(75)
Modafinil (N06BA07) Examine the safety profile of
modafinil in clinical usage across
a range of prescribing indications,
including off-label use
1,096;
20; 6
Additional safety and characterization of
real-life usage data, including in patients for
whom the prescribing indication is off-label.
Active surveillance post-license extension
A significant number of women of
childbearing potential had not been
commenced on appropriate contraceptive
programmes prior to starting modafinil.
The majority of events reported had been
previously documented. Stratification of
events according to dose revealed a
number of events that occurred at the
higher dose only, including serious events
such as psychosis
9
M-PEM
(60)
Carvedilol (C07AG02) Investigate adherence to risk
management recommendations
and to evaluate the safety profile
1,666;
57; 34
Assessment of compliance with prescribing
recommendations and clinical guidelines
post-license extension
Regulatory guidelines were mostly
followed, and most patients appeared to
benefit from treatment with carvedilol for
heart failure. Malaise/lassitude was the
main reason for discontinuing treatment
12
M-PEM
(120, 121)
Fluticasone (R03BA05) and
salmeterol and fluticasone
(R03AK06)
Evaluate the introduction of
metered dose inhalers with new
propellant into general practice
13; 413+13;
464;
19; 3
Studies conducted in response to RMP
requested to manufactures (active
surveillance pot-formulation change);
identification of off-label use
The introduction of CFC-free inhalers was
found to be generally well-tolerated
11
PEM
(73)
Aliskiren (C09XA02) Monitor the safety and use of
aliskiren prescribed in the primary
care setting
6,385;
40; 6
Monitoring the safety and utilization in real
life setting and complementing knowledge
from other sources, including SRS and
clinical studies
Aliskiren is largely being prescribed for its
licensed indication and is generally
well-tolerated. Renal events were common
in patients with risk factors for acute
kidney injury
10
PEM
(116, 118)
Testosterone (G03BA03) Describe utilization characteristics
and to quantify off-label use in
real-life clinical practice
3,073;
48; 6
Active surveillance of drug usage in a real-life
setting; identification and quantification of
off-label use indications (population not
included in RCT)
Only 20.9% of patients were being
prescribed the monitored drug according
to SPC recommendations
9
PEM
(62)
Vigabatrin (N03AG04) Compare the AE profile of children
and adults taking vigabatrin, using
modified SDMs
10,177;
55; 6
Contribution for assessing pediatric drug
safety; provide important information to the
sections of RMP linking to pediatric
investigation plan; detection of differences in
the safety profile (signals) between children
and adults
Quantitative SDMs used together with
clinical evaluation could identify possible
differences in the AE profiles between
children and adults
10
PEM
(104)
Levocetirizine (R06AE09) Monitor the safety of levocetirizine
prescribed in the primary care
setting
12,367;
19; 2
Safety analysis and characterization of real
life drug use
Levocetirizine is well-tolerated when used
in general practice in England. No
previously unrecognized ADRs were
detected
11
PEM
(61)
Lamotrigine (N03AX09) Compare AE profiles between
children and adults
9,836;
44; 6
Contribution for assessing pediatric drug
safety; provide important information to the
sections of RMP linking to pediatric
investigation plan; SDMs can be used to
detect quanti/qualitative differences in AE
profiles between children and adults
Differences in the AE profiles between
children and adults were observed.
Further, differences were observed in the
proportion of ADRs reported to regulatory
authorities between children and adults
11
(Continued)
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IM Studies ATC Aim Size (n);
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PEM
(69)
Oxcarbazepine (N03AF02) Monitor the safety of
oxcarbazepine prescribed in the
primary care setting
2,243;
47; 6
Assess the safety of drugs in a real-life
setting
The most frequently reported ADRs to
oxcarbazepine were drowsiness/sedation,
malaise/lassitude, nausea/vomiting,
confusion, and rash. There were no
serious ADRs reported
10
PEM
(117)
Strontium ranelate (M05BX03) Estimate the incidence of venous
thromboembolism during the first
12 months of treatment
10,782;
52; 12
Contribution to the ongoing postmarketing
safety assessment of strontium ranelate
The incidence of venous
thromboembolism is similar to estimates in
populations of similar age and
corresponds to the incidence found in
patients from RCT phase III and
observational studies of strontium ranelate
on this topic
11
PEM
(81, 99,
137)
Pioglitazone (A10BG03) Monitor the safety, describe the
risk management and outcomes,
and to investigate the relation
between characteristics and
incidence of hypoglycaemias in
patients prescribed pioglitazone
12,772;
16; 8
Useful methodology for postmarketing
surveillance (important pre-identified events
required monitoring as part of RMP);
identification of off-label use in patients with
limited treatment options
Pioglitazone was considered to be
reasonably well-tolerated (main reasons
for discontinuing: drug not being effective).
The frequency of ADRs did not exceed the
frequency in SPC. Pioglitazone was
associated with a low incidence of
hypoglycaemia. Timely drug withdrawal
and/or interventions can lead to
successful resolution of class AEs
11
PEM
(93, 94)
Taladafil (G04BE08) Examine the cardiovascular
safety, and to compare the
mortality rate due to ischaemic
heart disease in tadalafil users
with that in male population
16,129;
34; 12
Assess the occurrence of a specific AE
previously identified in RCT, SRS, and other
post-marketing studies
Tadalafil is generally well-tolerated when
used in general practice. The most
frequently reported AEs were in keeping
with RCT data and include headache,
dyspepsia and back pain. A similar
incidence of death due to ischaemic heart
disease in men prescribed tadalafil to that
in the male general population
12
PEM
(103)
Desloratadine (R06AX27) Monitor the safety of
desloratadine prescribed in the
primary care setting
11,828;
8; 6
Monitoring the safety of drugs and
complement the information generated from
RCT and SPR (AEs of interest)
Desloratadine is well-tolerated when used
in general practice. No previously
unrecognized ADRs were detected
10
PEM
(74)
Esomeprazole (A02BC05) Monitor the safety of
esomeprazole prescribed in the
primary care setting
11,595;
14; 6
Monitoring the safety of drugs under normal
clinical practice
The safety profile of esomeprazole was
consistent with the prescribing information
and experience reported in the literature
11
PEM
(98)
Rosuvastatin (C10AA07) Monitor the post-marketing safety
of rosuvastatin in primary care
setting
11,680;
11; 6
Monitoring the safety in the real life setting
and complement the information generated
from other studies on specific events
Rosuvastatin was considered to be a
reasonably well-tolerated drug.
Abnormality of liver-function tests was
found to be more frequent with the 40
mg/day dosage
10
PEM
(54, 122)
Sibutramine (A08AA10) and
orlistat (A08AB01)
Examine the safety profiles of
sibutramine and orlistat
12,336+16,021;
25; 6
Monitoring the safety in the real life setting
and complement the information generated
from other studies on specific events
The AEs identified are in agreement with
information from the SPC, other studies,
and published case reports
11
(Continued)
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PEM
(131)
Nateglinide (A10BX03) Examine the safety profile of
nateglinide as used in general
practice
4,557;
39; 6
Monitoring the safety in the real-life setting;
contribute to current knowledge regarding
safety during pregnancy
Nateglinide appeared to be generally
well-tolerated when used in combination
with metformin for the treatment of type 2
diabetes. No serious unlabelled AEs were
identified
10
PEM
(132)
Zafirlukast (R03DC01) Examine the safety profile of
zafirlukast as used in general
practice
7,976;
37; 6
Monitoring the safety of drugs in real life
setting, including population frequently
excluded from RCT (patients aged <12
years) and increase knowledge in elderly
where clinical experience is limited
Zafirlukast, as used in general practice, is
generally well-tolerated with few
associated AEs
10
PEM
(109)
Apomorphine hydrochloride
(G04BE07)
Examine the safety and use of
apomorphine as prescribed in
general practice
11,185;
21; 6
Monitoring the effectiveness and safety in
the real life setting and complement the
information generated from RCT on specific
events
The proportion of patients for whom
apomorphine was reported to be effective
was low. The most frequently reported
AEs were those listed in the SPC. A small
number of reports for unlabelled events
were thought by prescribers to be related
to the drug
9
PEM
(133)
Repaglinide (A10BX02) Examine the safety of repaglinide,
to quantify AE incidence and to
identify previously unrecognized
ADR
5,731;
32; 6
Monitoring the safety of drugs in real life
setting, identification of non-compliance and
increase of hypoglycaemia events with
starting treatment
Repaglinide is generally well-tolerated in
general practice and did not identify any
serious unrecognized AEs
10
PEM
(63)
Quetiapine (N05AH04) Examine the safety profile of
quetiapine as used in general
practice
1,728;
37; 6
Monitoring the safety, reasons for stopping
(e.g., ineffectiveness), off-label use in the
real-life setting
Quetiapine is generally well-tolerated when
used in general practice
10
Non-established intensive monitoring systems
HOS
(136)
Rituximab (L01XC02) Evaluate the long-term safety of
rituximab in rheumatoid arthritis
patients in daily practice
234;
60; 27.7
Confirmation the long-term safety profile of
this medicine in a refractory treatment
population. Emphasizes the need for a close
monitoring of treated elderly
Long-term rituximab therapy in a real-life
cohort did not reveal any new safety
issues. Advanced age was associated
with increased risk of AEs and premature
drug discontinuation
9
HOS
(127)
Unfractionated heparin
(B01AB01) and enoxaparin
(B01AB05)
Determine the incidence of
adverse outcomes in hospitalized
patients
488;
13; NM
Study on population frequently excluded
from RCT; identification of preventive
measures (lab monitoring, dose adjustment)
to reduce the risk of bleeding associated
with anticoagulation therapy
Anticoagulation among hospitalized
patients with CKD was significantly
associated with an increased risk of
bleeding and in-hospital mortality
10
HOS
(57)
Rituximab (L01XC02) Evaluate the frequency and
characteristics of ADR to
rituximab in patients with
non-Hodgkin’s lymphoma
550;
18; 0.01
Rituximab can be safely infused at a fast
rate. Fast infusions can be used at hospital
facilities and optimize treatment without
compromising safety
Rituximab had a favorable safety profile.
Contrasting with other studies, the risk of
ADR was higher for slow rate infusions.
The types of ADR were found to be similar
with other studies, whereas the ADR
incidence rate was lower
9
HOS
(101)
Iopromide (V08AB05), iodixanol
(V08AB09), iomeprol (V08AB10),
and iobitridol (V08AB11)
Describe the nature and quantify
the incidence of immediate or
delayed ADRs
1,514;
15; 0.2
Identification of a “signal alarm” that
recognizes anaphylaxis to contrast media as
an ADR; examine predictors of immediate
and delayed reactions
Both immediate and delayed ADR were of
predominantly minor or moderate severity.
These findings confirm that iodinated
contrast media have a good safety profile.
9
(Continued)
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IM Studies ATC Aim Size (n);
SD; DFU
Applications Conclusions QS
Monomeric low-osmolar contrast media
bear the major responsibility as causes of
immediate ADR, whereas dimeric contrast
media are mainly associated with delayed
HOS
(129)
Antiinfectives for systemic use (J) Assess the IR, risk factors, clinical
manifestations and causative
agents of antimicrobial-related
ADR
299;
5; 0.4
Importance of clinicians being familiar with
the manifestations of ADRs, since they are
highly prevalent and their occurrence mimics
other diseases and delay proper
management
The use of antimicrobial agents caused a
higher incidence of ADRs in hospitalized
patients as compared with studies from
western countries. Blood dyscrasias,
dermatomucosal effects, and febrile
reactions were the most common ADR
12
OTH
(97, 111)
Fluvastatin (C10AA04) Evaluate the long-term lipid
lowering efficacy and safety of
fluvastatin in Japan
21,139;
84; 60
Confirmation of efficacy and tolerability of
fluvastatin; detection of a substantial impact
of complications such as diabetes and
hypertension or low HDL-C on cardiac and
cerebral events
The results confirm the efficacy and
tolerability of fluvastatin. A low risk of
events in patients aged ≥65 years was
found. Long-term therapy with fluvastatin
elicited significantly greater improvements
in lipid control in patients aged ≥65 years
than in patients aged <65
10
OTH
(67)
Amiodarone (C01BD01) Assess the IR of ADRs associated
with the long-term use of
amiodarone and to describe their
characteristics
98;
82; 38
Conduct studies among population
frequently excluded from RCTs; monitoring
long-term safety of drugs
During amiodarone treatment, ADRs
occurred in 14 patients out of 100.
Hypothyroidism, cardiac ADRs, and
photosensitivity were the most frequent
ADRs and occurred mainly during the first
6 months
8
VAC
(110)
Influenza, influenza, live
attenuated (J07BB03)
Estimate the crude IR of AEIs
following vaccination with the
nasal vaccine in children and
adolescents
385;
3; 0.5
PASS study (European regulatory guidance
on enhanced safety surveillance for seasonal
influenza vaccines)
No significant change in reactogenicity or
other apparent safety signal from the data
collected has been detected
10
VAC
(123)
Pertussis, purified antigen,
combinations with toxoids
(J07AJ52) and influenza,
inactivated, split virus or surface
antigen (J07BB02)
Measure the reactogenicity of
trivalent influenza vaccine and
diphtheria-tetanus-acellular
pertussis vaccines administered
to pregnant women
5,155;
2; 0.2
Support the safety of antenatal vaccination Results support the safety of these
vaccines administered exclusively or in
combination during pregnancy, with a
slight increase in mild expected ADR.
Given the low incidence of systemic
reactions, these results support the safety
of antenatal influenza and pertussis
vaccination
10
VAC
(124)
Influenza, inactivated, split virus or
surface antigen (J07BB02)
Implement a real-time safety
monitoring program for trivalent
influenza vaccine administered to
pregnant women
3,173;
4.5; 0,2
Promoting confidence in vaccine uptake
particularly for pregnant women; mobile
phone technology proved an efficient
method for timely surveillance of AEFI
Results support the safety of this vaccine
in pregnant women. The low level of AEFI
observed should be reassuring to
antenatal patients and their providers and
could be used to help promote vaccine
uptake
10
VAC
(58)
Diphtheria-hemophilus influenzae
B-pertussis-tetanus-hepatitis B
vaccine (J07CA11)
Examine patterns of clinic and
emergency department visits,
hospitalizations and deaths in
children following vaccination
3,000;
24; 10
Capture all health care visits to monitor the
safety of new vaccines in low-middle income
countries
The liquid pentavalent vaccine was
associated with lower rates of health care
visits and not associated with increases in
SAEs or hospitalizations
10
(Continued)
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VAC
(59, 102,
114)
Influenza, inactivated, split virus or
surface antigen (J07BB02)
Assess the incidence and the
maternal-fetal impact of 2009
influenza pandemic, and the
effectiveness and the safety of
maternal vaccination
877;
14; 9
IM program for pandemic vaccines (general
population and pregnant women) was set
up by national authority. Information on
effectiveness/incidence of common AEFI of
vaccination
Incidence of pandemic flu was very low in
pregnant women. No effect on pregnancy
and delivery outcomes was evidenced
after vaccination. Seroprotection rate at
delivery appeared lower than expected in
vaccinated women
11
VAC
(113)
Influenza, inactivated, split virus or
surface antigen (J07BB02)
Assess the safety of an H1N1
vaccine during the national
vaccination campaign
9,143;
8.5; 7
PASS study advised by UK medicines
agency (implemented as a commitment to
authorities based on European
recommendations on pharmacovigilance
activities)
AS03-adjuvanted H1N1 pandemic
vaccine showed a clinically acceptable
reactogenicity and safety profile in all age
and risk groups studied
11
VAC
(82)
Influenza, inactivated, split virus or
surface antigen (J07BB02)
Investigate the safety of H1N1
vaccine in children and to explore
the feasibility of collecting AE data
through mobile telephone
contacts
359;
NM; 6
Feasible approach to assess the safety of
medicines in developing countries, such
Saudi Arabia
School-age children who received the
H1N1 vaccine did not have an increased
risk of hospitalization or emergency room
visits. Contacting caregivers is a feasible
approach to conduct studies
9
VAC
(55)
Influenza, inactivated, split virus or
surface antigen (J07BB02)
Estimate the frequency of AEs
following vaccination against
pandemic influenza A (H1N1)
2009 in children
156; 3; 1.3 Increase knowledge on special populations
(children) of vaccine safety data
Systemic AEs were more frequent than
local reactions at the vaccination site. IR
for AEs in general and systemic reactions
following the first dose were higher in
children with concomitant illness or allergy.
Most events were mild
12
VAC
(72)
Influenza, inactivated, split virus or
surface antigen (J07BB02)
Evaluate the effectiveness and
safety of H1N1 vaccines
601;
1; 1
Contribute to increase information on
efficacy and safety (complement the limited
information generated from RCT)
The two vaccines used in Tunisia remain
enough efficient to face H1N1 pandemic
and are well-tolerated
9
VAC
(135)
Papillomavirus (human types 16,
18) (J07BM02)
To assess the tolerability of the
2009 HPV vaccine catch-up
campaign
4,248;
18; 6.2
Improve knowledge of AE to increase
confidence in children vaccination;
monitoring variations in rates of AE in the
general population or in target group
overtime
After vaccination, girls reported particularly
pain at the injection site and myalgia. AE
after vaccination were dose dependent
(AE proportion decreased with dose) and
incidence increased with age. AEs were
mostly mild, and all were transient
11
VAC
(108)
Influenza, inactivated, split virus or
surface antigen (J07BB02)
Establish the feasibility of rapidly
monitoring the new swine flu
vaccines in large patient numbers
receiving or offered the
vaccination
4,066;
15; 7
Support the UK national strategy for H1N1
vaccine pharmacovigilance program; active
surveillance tool for ‘near real-time’ safety
monitoring with minimal additional workload
for HCP staff
No significant safety issues were identified.
The use of web-based technology was
successful in reducing costs and allowing
the collection of high quality data directly
from patients
9
VAC
(128)
Smallpox vaccine (J07BX01) Assess reported symptoms, vital
status, length of hospital stay, and
health-related quality of life status
of vaccinated patients
203;
14; 9
Better knowledge about clinical implications
of administering smallpox vaccine focusing
on specific adverse cardiovascular events
(complement information generated from
SRS)
Although intermediate-term consequences
among AEFI were not considered serious,
lost days of work and a decline in
health-related quality of life at the time of
follow-up were common, resulting in
personal economic and quality-of-life
burden
7
(Continued)
F
ro
n
tie
rs
in
M
e
d
ic
in
e
|
w
w
w
.fro
n
tie
rsin
.o
rg
1
4
Ju
ly
2
0
1
9
|V
o
lu
m
e
6
|
A
rtic
le
1
4
7
To
rre
e
t
a
l.
In
te
n
sive
M
o
n
ito
rin
g
S
tu
d
ie
s:
S
yste
m
a
tic
R
e
vie
w
TABLE 3 | Continued
IM Studies ATC Aim Size (n);
SD; DFU
Applications Conclusions QS
VAC
(96)
Hemophilus influenzae B, purified
antigen conjugated (J07AG01),
pertussis, purified antigen,
combinations with toxoids
(J07AJ52), pneumococcal
vaccines (J07AL), tetanus toxoid,
combinations with diphtheria
toxoid (J07AM51), influenza
vaccines (J07BB), hepatitis B,
purified antigen (J07BC01),
poliomyelitis vaccines (J07BF),
rubella, combinations with
mumps, live attenuated
(J07BJ51), and varicella, live
attenuated (J07BK01)
Evaluate the safety of
simultaneous vaccination and the
frequency of adverse reactions
772;
27; 0.2
Increase the acceptance of simultaneous
vaccination
Simultaneous vaccination is feasible for
Chinese applicants for a USA immigrant
visa because the adverse reactions are
mostly mild and temporary
9
VAC
(79)
Diphtheria-hemophilus influenzae
B-pertussis-tetanus-hepatitis B
(J07CA11)
Document the AEFI associated
with a newly introduced
pentavalent vaccine in infants
406;
16; 3
Obtain information on the incidence of
common AEFI of the new pentavalent
vaccine; strengthen the nascent AEFI
system in a resource-limited country
The results show agreement with safety
studies on vaccines containing identical or
similar antigens and indicate the safety
and tolerability of the pentavalent vaccine
in Ghanaian children
8
ADR, Adverse Drug Reaction; AE, Adverse Event; AEFI, Adverse Event Following Immunization; CEM, Cohort Event Monitoring; DFU, Duration of Follow-up (months); GP, General Practitioners; HOS, Hospital care level; IMMP, Intensive
Medicines Monitoring Programme; IM, Intensive Monitoring; IMS, Intensive Monitoring System; IR, Incidence Rate; LIM, Lareb Intensive Monitoring; M-PEM, Modified-Prescription Event Monitoring; NM, Not mentioned; OTH, Others;
OQS, Overall Quality Score; PASS, Post-authorization safety study; PEM, Prescription Event Monitoring; RCT, Randomized Clinical Trial; RMP, Risk Management Plan; SADR, Serious Adverse Drug Reaction; SD, Study Duration (months);
SDM, Signal Detection Methods; SPC, Summary of Product Characteristics; SRS, Spontaneous reporting system; VAC, Vaccines.
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of 14) targeted vulnerable populations (e.g., children, pregnant
women). These studies were carried out using different methods
for data collection (HCP face-to-face/web-based/telephone or
mobile text messages). The median follow-up time observed was
4.5 months (range: 0.2–10) and themedian study duration was 14
months; range: 1–27). The main limitations were non-response
bias, non-representativeness, the lack of a control group, small
sample size to detect rare outcomes (e.g., autoimmune diseases)
and information bias (e.g., recall bias, adverse events following
immunization (AEFI) not clinically confirmed).
IM non-established system studies classified as “Others”
covered only drugs from cardiovascular system ATCmain group.
Regarding hospital-based studies, a wide range of drugs were
monitored, although the median number of patients included
was lowest (488) within all reviewed studies. Regarding funding
sources, 8 out of the 21 studies did not mention the source
of funding, 7 were supported by governmental institutions, 3
from the pharmaceutical industry, 1 from a non-governmental
organization, and 2 reported no sources of funding.
Overall Quality Score
The mean overall quality score (OQS) was 9.7 out of 13 (range:
7–12), being similar between established (9.9; range: 6–12) and
non-established (9.7; range: 7–12) IM studies. Among established
IM studies, M-PEM and PEM presented the highest mean OQS
(10.5 and 10.3, respectively). Detailed results about OQS of each
reviewed study are shown in Additional File 3.
DISCUSSION
In the decade following the paradigm shift in medicines
regulatory systems, from a largely reactive response to a
more proactive approach to drug safety issues (2006–2016),
we thorough examined IM methodological features for data
collection and analysis, population surveilled, limitations and
its applications in the daily practice environment. IM studies
reviewed were implemented in 26 countries with different
maturity levels of post-marketing surveillance systems. IM
systems operated either in countries with non-existing or weak
monitoring SR schemes, such as sub-Saharan African countries
(23, 139), or in countries that have the most widely used record-
linkage databases in the world for drug research, such as the
UK (e.g., Clinical Practice Research Datalink) (140) or the
Netherlands (e.g., PHARMO) (141)—picturing the contribution
of IM systems in the real-world evidence generation data.
Regardless the differences found within the methodologies used,
these schemes were developed with the purpose of filling the
gap between RCT (high internal validity and low external
validity) (142, 143), SR data (limited by under and selective
reporting) (25, 144) and automated database studies (their large
size and their longer follow-up times and representativeness
make it possible to study real-world effectiveness and safety,
but they are usually poor in detailed covariate data) (145, 146).
Based on event monitoring and by tracking patients and
drug use in a life-cycle based fashion, the results originating
from IM studies encompasses the identification/quantification
of factors that possibly negatively affect the benefit/risk balance,
including (new) adverse events (identification and strengthening
of signals), increase of knowledge of drug utilization patterns,
identification of off-label use, among others. Moreover, by
collecting longitudinal data since the first day of drug use, it
allows to follow the time course (latency time and duration),
outcome and management (to help clinicians and patients to
adequate predicting with handling ADE, improving adherence
and avoid early-discontinuation) of ADE; information that very
few post-authorization methods can provide.
In the beginning of the century, Waller and Evans (147)
argued that pharmacovigilance should be less focused on finding
harm and more focused on extending knowledge of safety. Since
then, the regulatory landscape has evolved and in parallel, an
endeavor of post-marketing active surveillance schemes to meet
the new regulatory challenges was witnessed. IM systems were
no exception. For example, in the UK, PEM moved toward
a more target surveillance: M-PEM. In the latter, efforts are
done to better understand known or partially known drug risks
(e.g., target analysis of events requiring special monitoring, more
detailed characterization of drug usage, adherence to prescribing
guidelines) and an alignment with regulatory requirements (e.g.,
PASS as part of RMP), is explicitly described as applications of
this scheme. Further, the target sample size of 10,000 patients
in conventional PEM-studies, which was driven by sensitivity
assumption to detect rare and uncommon events was abandoned
in M-PEM studies, where a specific sample size is calculated
depending on the research question of interest (18). Some
authors argue that IM is not an efficient way to detect these
frequency-type events and for that purpose, other methods
should be considered. For example, SR would probably be a more
suitable method followed by an analytical study to confirm the
signal (85). Likewise, the limited follow-up time duration does
not allow for the detection of long-term events (e.g., cancer).
On the whole, drugs monitored through the reviewed studies
were in the early post-marketing phase or were characterized
by uncertainties concerning specific safety issues, namely those
identified in the RMP (safety concerns raised from RCT, post-
marketing experience and/or suspicion of inappropriate drug
use). This was generally in line with IM drug entry decision
criteria previously described by Coulter (19) and more recently
by Harrison-Woolrych (148). Also, noteworthy that older drugs
can be studied within this methodology. This was the case of
metformin, marketed 60 years ago, where relevant information
from the daily practice perspective, such as the outcome,
management and the time course of metformin related ADE was
lacking (77). We also observed that two-thirds of CEM studies
were launched in resource-constrained settings and developed
for monitoring artemisinin-based combination therapy for
malaria treatment, aiming to complement information from
RCT. In recent years, CEM was adapted and covered other
drugs, such as antiretrovirals (126), vaccines (76), among others.
Overtime, some practical handbooks have been issued by the
WHO to support the implementation of specific programs
[malaria (149), HIV/AIDS (150), and tuberculosis (151)]. The
experiences of countries that have implemented CEM indicate
that this was a key opportunity to raise awareness and to
build pharmacovigilance capacity in these settings, which can
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be expected to have a positive effect on SR activities in the
long run (23). The latter is of importance, since there is a
need to strengthen ADR reporting rates in low-income countries
and IM studies could be used in national pharmacovigilance
systems (152).
Despite IM features found worldwide, the majority of
monitored drugs were prescribed at the primary care level,
highlighting the limited research in hospital and other secondary
settings, either among established or non-established IM studies.
At hospital level, where the drug market is rapidly changing,
with more and more new drugs being introduced (e.g., cancer,
autoimmune diseases, infectious diseases, etc.) (153), it seems
that automated databases or often registries (drug registries
or frequently disease registries) supplement IM systems. This
might be partially due to efficiency reasons tied with decisions
taken at an early stage dialogue with regulatory agencies. A
recent study (154) revealed that one third of drugs approved
in Europe (2007–2010), were coupled with a requirement for a
registry, mainly with the purpose of gathering additional safety
data. Most of the registries involved were derived from existing
disease registries, i.e., designed for other purposes. The latter
feature is seen as an advantage of this source due to efficiency
reasons. However, it could also represent a weakness, since the
multipurpose nature of registries frequently means that they are
often organized for broader questions and therefore are limited
by their heterogeneity in safety data collection and reporting
(155). In other words, they may lack a focused hypothesis
since they are viewed as a data collection structure within
which studies can be performed rather than a study aimed
at answering a specific research question (16, 17, 153). It is
also important to cover drugs prescribed by specialists, where
patients are frequently more complex in terms of underlying
disease and co-morbidities. This drawback was not a reality
within LIM studies, where the inclusion point was commonly
the community pharmacy, but was the case of PEM/M-PEM. In
the UK, to overcome this, a new IM system is being developed:
the Specialist Cohort Event Monitoring (SCEM). A few SCEM
studies are ongoing: OBSERVA—Observational Safety Evaluation
of Asenapine and ROSE—Rivaroxaban Observational Safety
Evaluation, both in response to post-authorization commitments
requested by the European Medicines Agency (156).
Over the study period, the reviewed IM studies were not
restricted to safety data collection. Other domains of drug
outcomes, such as drug utilization patterns (both in terms
of prescriber characteristics and patient population) and in a
less extent, effectiveness (“therapeutic response”) were studied.
Concerning safety, our review illustrated a high degree of
variability and a lack of standardization. Regardless of causality
assessment, terms such as “adverse event” and “adverse reaction”
were often used interchangeably, without explicit definitions to
ensure consistency of use. In PEM and IMMP methodology the
reported information was treated as adverse events. However, in
LIM studies it was stated that although a causality assessment
was not performed, the term ADR was used for the reactions
reported as the authors claimed that patients were asked only to
report symptoms that they believed to be associated with the use
of the monitored drug. In this review, we used the terms reported
by the authors but we encourage developing methodological
and guidance safety reporting standards, for example through
scientific and collaborative working groups at international
level (e.g., International Society of Pharmacovigilance and
International Society for Pharmacoepidemiology).
Patients and caregivers were the event data source in 39.1%
of the studies. Overtime, the evolving regulatory landscape has
heightened the recognition of patients as important players
in clinical practice (157). Since 2012, in the European Union,
patients can report ADE directly to competent authorities.
Nevertheless, the concept of patient reporting schemes is far from
new—it has been around for more than 50 years (158). Studies
on patient reporting have demonstrated the ability of early
identification of new and strengthening potential safety signals
(159–161). Moreover, reports of symptomatic non-serious ADE
from PCG are of great importance, since these events are often
systematically downgraded by HCP, though they play a negative
role on patients’ quality of life and adherence to treatment, and
ultimately on the benefit-risk of a drug. On the contrary, PCG
could be less valuable to detect asymptomatic or serious or fatal
events (162–164).
As any other primary data collection study, IM schemes are
costlier and labor intensive. In a recent survey documenting the
experiences of four African countries with CEM programmes
(23), limited/inadequate funding was often considered as a
challenge to deal with. This constraint was also reported in
the New Zealand, where due to funding cessation, IMMP was
disestablished in 2013 (148). It also seems that Japan-PEM (J-
PEM) is no longer operational, since no published study from
this scheme was found within the timeframe of our study. The
J-PEM was launched in 1997 (165) and at least two pilot studies
were conducted: troglitazone (166) and losartan (167). Although,
J-PEM employed the method of a concurrent-control, which
represented an advantage when compared with the majority
of the reviewed IM studies, it appeared to be rather complex
concerning data protection and managerial issues (22).
Low response rate and/or non-response bias was frequently
mentioned as a limitation of both established and non-
established IM system studies. A postal survey aiming to identify
reasons for non-response in PEM studies (168), found workload
and lack of payment, as the main reasons for non-response.
In M-PEM studies, GP were offered a modest reimbursement
for completion of questionnaires, which had a positive impact
on the response rate (the median response rate increased from
50% in PEM to 64% in M-PEM) (18). Moreover, unforeseen
challenges when conducted CEM studies were found, namely
socio-cultural reasons that led to selective/non-participation
(e.g., in Kenya some women could not give informed consent
without permission from their husbands) (23). In LIM studies,
non-response bias was also investigated (169). The major reason
for non-response raised by patients was the fact that the study
was not (properly) informed in the pharmacy. Further reasons,
such as time-consuming, no-access to internet or being too
ill to participate, were also pointed out (170). For external
validity purposes, it is important to know whether IM population
is comparable to the whole population using the monitored
drug. Härmark et al. (171) found that LIM population were
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more often male, younger and healthier (higher percentage of
de novo treated patients, shorter disease treatment duration
and less co-medication) than the reference population. The
authors concluded that these differences might lead to an
underestimation of events, however it was not clear whether this
influenced their time-course.
Our systematic review is subject to some limitations. Firstly,
unpublished research (gray literature, reports) was not captured
by our search strategy and therefore not included in this
study. Secondly, we acknowledge that our review is limited
by what authors have reported or presented in their studies.
However, an assessment of quality was performed for all reviewed
studies. Despite these limitations, we believe that our results
are relevant and represent the first systematic review with
the most comprehensive information available of IM systems
implemented worldwide.
CONCLUSIONS
Over the study period, IM studies were implemented in
26 countries with different maturity levels of post-marketing
surveillance systems, picturing the contribution of IM schemes
in the real-world evidence generation data. Based on event
monitoring and by tracking patients and drug use in a life-
cycle based fashion, specific applications of the reviewed studies
covered the following: increase of knowledge of drug safety
data profile (outcome, time-course and management of ADE)
identification of potential unrecognized and unsuspected ADE
(tool for signal generation), gathering ADE data in resource
limiting settings from populations frequently excluded fromRCT
(pregnant women, pediatrics and elderly), increase of knowledge
of drug utilization patterns, and identification of off-label
use. Overtime, an alignment with regulatory requirements was
observed, where some studies have been undertaken to address
specific questions related to safety concerns and drug utilization
patterns (e.g., phase IV assessment as part of the RMP).
Framed onto the scope of IM systems implementation criteria,
we identified two major limitations. Unexpectedly, only 20% of
reviewed studies were conducted at hospital-level, which is a
matter of concern, insofar as healthcare systems are facing a
lack of access to new medicines at ambulatory care level (e.g.,
issues concerning pricing/reimbursement), and there has been a
shift of new drugs introduction to hospital setting. Additionally,
IM access to data of (new) drug exposure cohorts, either at
identification or at follow-up stages, could somehow constitute a
barrier, given the complexity of managerial, linkable and privacy
data issues.
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